At the 61st ASH Annual Meeting & Exposition, Sabina Chiaretti, “Sapienza” University of Rome, discusses her presentation: Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. A Single Center Experience.
1. What are the limitations of current therapeutic options for patients with relapsed/refractory acute lymphoblastic leukemia (ALL)? (0:05)
2. What is the mechanism of action of blinatumomab? (0:54)
3. What were the major findings of your retrospective study? (1:46)
4. What did the study findings teach us about the safety profile of blinatumomab and how to manage toxicities? (2:58)
5. How are these findings likely to impact on clinical practice? (4:43)
Sabina Chiaretti has received consultancy fees from Amgen, Shire, Pfizer and incyte.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
Share this Video
Related Videos In Leukaemia
Andreas Hochhaus, ASH 2020 – The ASCEMBL Study and Asciminib in CML
touchONCOLOGY meets with Prof. Andreas Hochhaus to discuss the clinical development of asciminib and its potential as a therapy for chronic myeloid leukaemia. The abstract ‘Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic […]
Othman Al-Sawaf, ASH 2020 – Venetoclax-obinutuzumab and the CLL14 Trial
Dr Othman Al-Sawaf joins touchONCOLOGY to discuss the CLL14 trial and the impact of venetoclax-obinutuzumab treatment on clonal growth and the potential of its use in chronic lymphocytic leukaemia. The abstract ‘Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial’ (Abstract number 127) was presented at the 62nd American Society […]
Massimo Breccia, ASH 2019: Discontinuing Tyrosine-kinase Inhibitors in patients with Chronic Myeloid Leukemia
At the 61st ASH Annual Meeting & Exposition, Massimo Breccia, Sapienza University of Rome, discusses discontinuing tyrosine-kinase inhibitors (TKIs) in patients with chronic myeloid leukemia. Questions 1. What is the rationale for discontinuing tyrosine-kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML)? (0:05) 2. Following discontinuation of TKIs in patients with CML, when are […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!